Therapeutic Vaccine Shows Promise in Treating Lung Cancer .
SINGAPORE — A Few Months After Releasing its Phase I and II Data, OSE Immunotherapeutics, Which is Based in Nantes, France, Has Announced Positive Results For Its Therapeutic Vaccine To Treat Cáncer .
Following Its Promising Findings Concerning Early-Stage Melanoma, Pancreatic Cáncer, ENT Cancers, and HPV-Associated Anogenital Cáncer, The Company-Funded Phase III Atalante-1 Trial Has Shown The Benefits of The TEDOPI (OSE2101) Vaccine in Treating Patients With Advanced Non–Small Cell Lung Cáncer Who Are on Their SECOND-LINE or THIRD LÍNE of Treatment .
The Data From Atalante-1 Were Presented at The World Conference on Lung Cancer And Were Simultaneously Published in Annals of Oncology .
.jpeg)